Heritable molecular defects in secretory and endocytic pathways that regulate BACE1 processing of APP may increase Aβ production, further implicating BACE1 and amyloid in AD, and may be targeted for developing AD therapies [70]. Here, BACE1 is linked to Alzheimer disease.